Identification of new biomarkers about Langerhans cell histiocytosis using mass spectrometry

2016 Fiscal Year Final Research Report

• Project/Area Number: 26460451
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Human pathology
• Research Institution: Kochi University (2015-2016); Tottori University (2014)
• Principal Investigator: MURAKAMI Ichiro 高知大学, 教育研究部医療学系連携医学部門, 教授 (80548701)
• Co-Investigator(Renkei-kenkyūsha): OKA Takashi 岡山大学, 医歯薬総合研究科, 講師 研究者 (50160651)
• Project Period (FY): 2014-04-01 – 2017-03-31
• Keywords: ランゲルハンス細胞組織球症

Outline of Final Research Achievements

Plasma sample from 12 patients with LCH-RO (－) (5 MS-LCH and 7 SS-LCH) and 5 non-LCH patients were analyzed by peptidomics. Mass spectrometry (MS) spectra were　acquired and peptides exhibiting quantitative differences between MS-LCH and SS-LCH patients were targeted.
One new candidate biomarker, m/z 3145 was selected and identified after obtaining a MS/MS fragmentation pattern using liquid chromatography-MS/MS. This peak was　identified as a proteolytic fragment derived from interalpha-trypsin inhibitor heavy chain 4 (ITIH4, [PDB: Q14624]).
Peptidomics of LCH have revealed that the level of acute-phase ITIH4 distinguishes MS-LCH-RO (－) from SS-LCH-RO (－). Acute-phase proteins serve non-specific,　physiological immune functions within the innate immune system. LCH may be a　reactive disorder with both underlying neoplastic potential of antigen presenting　cells harboring BRAF mutations and hyper-immunity of other inflammatory cells　against MCPyV infection.

Free Research Field

人体病理学